June 2nd 2025
Researchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Lymphocyte Infusion Effective Following CML Relapse After HSCT
July 14th 2014Lymphocyte infusions are extremely effective therapy in patients with chronic myeloid leukemia who relapse after allogeneic hematopoietic stem cell transplantation, and the timing of the infusion is relatively unimportant, according to a new study.
Lenalidomide Confers Greater QoL vs Thalidomide in Multiple Myeloma
June 16th 2014A comparison of melphalan, prednisone plus either thalidomide or lenalidomide found that patients assigned to lenalidomide had fewer grade 3 or higher toxicities and a better quality of life at the end of induction therapy.
Cardiovascular Toxicity of Biologic Agents for Cancer Therapy
June 15th 2014This review will focus on newer FDA-approved targeted therapies associated with type II chemotherapy-related cardiac dysfunction, or generally reversible cardiotoxicity, and will provide the latest information on the incidence and clinical spectrum of cardiotoxicity associated with each therapy, modifiable risk factors where known, and the mechanisms of cardiotoxicity.
Panobinostat Improves PFS in Relapsed, Refractory Multiple Myeloma
June 13th 2014Treatment of relapsed or refractory multiple myeloma with the three-drug combination of panobinostat/bortezomib/dexamethasone resulted in a nearly 4-month improvement in progression-free survival compared to treatment with bortezomib/dexamethasone alone.
Ibrutinib Shows Huge Benefit Over Ofatumumab in CLL and SLL
June 5th 2014Ibrutinib substantially increased progression-free survival and overall survival over ofatumumab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to the results of the RESONATE trial.
Continuous Therapy Best in Newly Diagnosed Multiple Myeloma
June 3rd 2014Continuous therapy produces drastically better progression-free survival and overall survival outcomes in patients with multiple myeloma. A novel endpoint involving time to second progression is an important tool in evaluating this type of treatment in the future.
Atypical CML Distinct From Related Myelodysplastic/Myeloproliferative Disorders
May 7th 2014A rare subtype of disease known as atypical chronic myeloid leukemia (aCML) has been shown to be clinically distinct from a related condition known as unclassifiable myelodysplastic/myeloproliferative neoplasm.
Diffuse Large B-Cell Lymphoma: One Treatment No Longer Fits All
April 15th 2014Rationally designed clinical trials investigating novel agents in patient populations enriched for those who are most likely to benefit will be instrumental for expediting progress. With respect to DLBCL, it has become clear that one treatment no longer fits all.
Diffuse Large B-Cell Lymphoma: Changing Treatment Paradigms
April 15th 2014With the progress in diagnostic methods that has made it possible to decipher the genetic code of DLBCL within a relatively short time, and with the increasing number of drugs that are entering clinical trials, our next big challenge is to enroll patients in trials in a timely manner.
Appropriate Management of Molecular Subtypes of Diffuse Large B-Cell Lymphoma
April 15th 2014The classification of diffuse large B-cell lymphoma into three distinct molecular diseases--germinal center B-cell–like subtype, an activated B-cell–like subtype, and a primary mediastinal B-cell lymphoma subtype--has laid the foundation for the development of new agents and novel strategies that target individual subtypes.